GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Q

Qyuns Therapeutics Co 2509.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

14.50

+1.19%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Qyuns Therapeutics Co

Its shares trade on HKEX under the ticker 2509.HK. It has been listed since 20 March 2024. In the fiscal year to 30 September 2025, it reported revenue of CN¥915.7m and net income of CN¥356.8m. At that date it held total assets of CN¥1.86bn and shareholders' equity of CN¥808.8m.

Qyuns is developing six candidates, most of them interleukin antibodies. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2024-03-20. The firm has eight programs under research and development, and the target indications include psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and asthma, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
20 Mar 2024
Employees
323
Website
qyuns.net ↗

Leadership

Pay as last reported

  • Mr. Zhiqiang WuNon-Executive Director
  • Mr. Xi YuNon-Executive Director, since 2020
  • Mr. Jiwan QiuExecutive Chairman of the Board, Chief Executive Officer, General Manager, since 2015
  • Mr. Weidong LinExecutive Director, since 2022
  • Mr. Yiliang WuExecutive Director, since 2019
  • Mr. Che Wai FungIndependent Non-Executive Director
  • Dr. Jianqun LingIndependent Non-Executive Director
  • Dr. Zhongmei ZouIndependent Non-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company has six development candidates, primarily interleukin antibodies.
  • It has eight R&D programs targeting multiple inflammatory conditions.
  • The company went public on 2024-03-20 with 323 employees.

Weaknesses

  • The company's sector and industry are listed as N/A.
  • The company's headquarters location is in Taizhou, Jiangsu, which may limit market reach.
  • The company has no disclosed revenue or financial performance data.

Opportunities

  • The company's focus on interleukin antibodies could address unmet medical needs.
  • Expanding R&D programs may lead to new therapeutic approvals.
  • The IPO in 2024 provides capital for further development.

Threats

  • The company's sector and industry being N/A may hinder investor confidence.
  • The lack of disclosed financial data could raise concerns about sustainability.
  • Competition in the biotech sector may impact R&D success.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.